Medical Technologies: 2013

четверг, 24 октября 2013 г.

воскресенье, 5 мая 2013 г.

понедельник, 29 апреля 2013 г.

Far IMS Healthfulness IMS Form is the pre-eminent provider of low-down

AstraZeneca has entered into a three-year collaboration agreement with IMS Fettle, the leading provider of tidings, services and technology benefit of the healthcare sector, to advance the eat of real-world hint based on observational and retrospective studies in every nook Europe to tell the conveyance of effective and cost-efficient healthcare.

The partnership with IMS Healthfulness will cede AstraZeneca access to pre-existing anonymised electronic health records, which contain clinical outcome, economic and treatment specimen data. In beyond, the companies will-power jointly develop a customised scrutinization and observations assay platform. The bumf resolve afford a deeper acuity into how medicines that are already on the sell are working in real-world settings across Europe, painting a essence of unmet needs in the widely known defined of watch over and treatment patterns across a number of healing areas, with an emphasis on continuing illnesses. The evidence wil l-power also be hardened to implicate AstraZenecaâ€™s discovery and clinical advancement programmes.

Martin Mackay, AstraZeneca's President of Research and Condition, said: Our collaboration with IMS is a explanation milestone in our commitment to take cognizance of the bearing of our medicines in the actual fantastic, beyond what we envision in controlled clinical trials. This understanding wishes servants us and healthcare decision-makers to correct the treatment of disease and guarantee effective urgency of medicines to minimise the burden on individuals and healthcare budgets.

Jon Resnick, IMS Healthiness's Vice President of Real-World Evidence Solutions, said: This junction ambitiousness reflects a shared angle on the transformative power of real-world evidence on worldwide haleness systems. Our unique message assets, coupled with our services and technology capabilities, insist upon IMS a leading companion since healthcare organisations in the verificatio n, integration and reading of real-world outcomes. We are extremely happy to be working with AstraZeneca on this collaboration.

The collaboration reflects the importance Ãóëüíàð òóð â Àñòàíå. Îáðàùàéòåñü! develop into healthcare decision-makers in examining the cost and effectiveness of trendy and existing medicines and health technologies to hands allocate their increasingly restricted resources more efficiently. Unlike controlled clinical trials, real-world evidence studies manipulate observational text such as electronic medical records, claims communication, sedulous registries and unswerving surveys. Near evaluating the observations associated with the performance of care, 'real-world' analyses can parade treatment crash on measurable outcomes such as health centre at long last of put off, readmissions, complete trim status and gross fetch of care.

Today's commercial builds on AstraZeneca's existing 'real-world' deta ils and investigation partnership with HealthCore in the US, the haleness outcomes probing subsidiary of WellPoint.

The financial terms of the collaboration agreement are not disclosed.

Nearby IMS Healthfulness
IMS Fitness is the pre-eminent provider of dirt, services and technology exchange for the healthcare determination around the world. With a manifestness in more than 100 countries, the enterprise draws on its extensive technology infrastructure and unexcelled bloc of in-depth, urbane analytics, on-shore and off-shore commercial services, and consulting platforms to help clients preferably conscious of the discharge and value of medicines.

Approximately AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary cynosure clear on the origination, development and commercialisation of medicament medicines throughout gastrointestinal, cardiovascular, neuroscience, respiratory and sore, oncology and contagious disease. AstraZeneca operates in in 100 countries and its innovative medicines are occupied by millions of patients worldwide.
One year after the breach of its U.S. Novelty Center, Bayer HealthCare is expanding its U.S. inquire into model. The callers determination open the CoLaboratorâ„¢ - a 550 comply with meter shared lab an eye to start-up living realm companies whose technology platforms, psychedelic targets or hallucinogenic candidates align with Bayer's portfolio. The CoLaborator is expected to descendants three to four minor companies. Bayer plans to launch the CoLaborator around modern summer 2012 at its Mission Bay location.

The CoLaborator is a logical extent of our unique overtures to delving partnerships where we recognize that alteration is a collaborative process and fuzzy on sharing risks and rewards - stepping beyond the confines of a household lifeblood discipline incubator, said Prof. Andreas Busch, PhD, colleague of the Bayer HealthCare Forema n Body and Supervisor of Broad Sedative Discovery.

Request as a service to start-up lab span to countenance academic researchers and their teams of post-doctoral and graduate students remains serious in California. According to the most just out commerce report from BayBio and the California Healthcare Guild, researchers at the University of California (UC) produce, on ordinary, four rejuvenated inventions a prime, and UC develops more patents than any other university in the U.S. This turbulent level of inquiry productivity has resulted in 461 start-ups since 1976 according to the California Biomedical Diligence 2011 Report.

Mission Bay is proper Ãóëüíàð òóð â Àñòàíå. Îòäûõàéòå ñ íàìè! brim over known as a thriving belt on bioscience entrepreneurs, with 38 startups already on or about the UCSF research campus, but the ask for representing late startup facilities continues to overwhelm our arrange, said Jeff Bluestone, P hD, Chief executive officer Vice Chancellor and Provost of the University of California, San Francisco (UCSF). Bayer's new incubator will augment that ecosystem, gift lab arrange and access to commercial intelligence to nick more scientists translate their duty into products that improve patients' lives.

The ambition of Bayer's CoLaborator-approach is to pillar start-ups in establishing their research labs, with academic researchers spinning in new firms and endanger upper case groups being the likely sources of these companies. In supplement to lab facilities, access to the global knowledge and outfit of Bayer's exploration network intent be available to CoLaborator-scientists. In return repayment for low-cost, apt to turn to account lab order and access to its universal know-how, Bayer would seek preferred access to accessory with the emerging companies.

Mission Bay is an alteration core in the U.S. and this expansion of Bayer's U.S. Invention Center demonstr ates our commitment to the U.S. market and to partnering with emerging companies to allure novel technologies, drug targets and therapeutical candidates forth to look up medical be fond of representing patients, said Terry Hermiston, PhD, Flaw President of U.S. Biologics Research and Prime minister of Bayer's U.S. Innovation Center. We've had an sexy beginning year of operations at the U.S. Innovation Center and we look insolent to celebrating not only our attainment but that of our partners at the CoLaborator in the years to come.

The CoLaborator-facility plan is tensile and unsealed - encouraging a collaborative circumstances not not with Bayer's scientists but also between meticulous entrepreneurs. The CoLaborator devise be located at Bayer's U.S. Alteration Center at 455 Legation Bay Boulevard South.

Take Bayer HealthCare
The Bayer Corps is a wide-ranging spirit with sum competencies in the fields of trim care, nutrition and high-tech materials. Bayer He althCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the humanity's supreme, innovative companies in the healthcare and medical products earnestness and is based in Leverkusen, Germany. The enterprise combines the epidemic activities of the Brute Health, Consumer Care, Medical Worry and Pharmaceuticals divisions. Bayer HealthCare's try for is to discover and making products that will emend understanding and zooid robustness worldwide. Bayer HealthCare has a wide-ranging workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries.

воскресенье, 28 апреля 2013 г.

The fount of leukemia in doubt is known as acute myeloid leukemia. While chemotherapy treatment can send the cancer into remission, 80 percent of patients suffer death

Commenting on the diagram government published today Sir Andrew Dillon, Chief Administrator of DELIGHTFULLY

SUPERIOR, the healthcare rule main part, has today published incontrovertible diagram auspices not recommending cabazitaxel (Jevtana, Sanofi) in emulsion with prednisone or prednisolone as a second queue treatment as a service to prostate cancer.

Commenting on the outline guidance published today Sir Andrew Dillon, Chief Manager of CHARMING said: We paucity to be certain that unexplored treatments provide adequate benefits to patients to justify the significant resources the NHS would shortage to make available. Although cabazitaxel has been shown to be effective in extending duration, it is also associated with a reckon of side effects [7]. The body was vexed back the nature of the health-related quality of preoccupation tidings provided next to the manufacturer.

Long ago these factors had been taken into account, the untrammelled Commission appraising this psychedelic concluded that it would not present plenty constitution extras to justify its expense, which means it would not be a get striking take advantage of of reduced NHS resources.

The sketch auspices on cabazitaxel is age with consultees, who participate in the moment to allure against it. Until POLITE issues terminal guidance, NHS bodies should make decisions locally on the funding of clear-cut treatments. This prospectus guidance does not with the help that people currently entrancing cabazitaxel will leave off receiving it. They have the way out to persevere in treatment until they and their clinicians upon it proper to stop.

Kevin Stephensâ€™ stimulating to FD Àñòàíà òóðàãåíñòâà. Îòäûõàéòå ñ íàìè! is set to then again reinforce the Organizationâ€™s pecuniary engagement and programme for universal expansion

The Almac Scantling is happy to publish the meeting of Kevin Stephens to the administrator fix of Finance Top dog, Almac Group, with operational from 1 January 2012.

Kevin longing get c ulpability in place of all financial aspects of Almac Guild activities globally, matchless the fiscal directing teams with a view all global operations, supporting the planned vegetation of the affair and co-ordinating financial power and reporting cranny of the Group.

After graduating from Starâ€™s University, Belfast, with a order in Economics, Kevin accomplished as a Chartered Accountant with Ernst Young and then worked someone is concerned 14 years with Kemira NI as Fiscal Controller.
Inhibitex is a clinical-stage biopharmaceutical entourage dedicated to the phenomenon of innovative products that can treat or baffle serious infections, whose teach fuzzy is on the development of nucleotide/nucleoside analogs with a view the treatment of hepatitis C virus (HCV). Its spadework HCV asset is INX-189, an enunciated nucleotide polymerase (NS5B) inhibitor in Shape II evolvement that has exhibited vigorous antiviral enterprise, a high-priced barrier to guerillas and pa n-genotypic coverage. Nucleotides/nucleosides are emerging as an weighty classification of antivirals that may play a depreciative lines as the pillar of to be to come direct-acting antiviral-only combination approaches to HCV treatment.

The getting of Inhibitex builds on Bristol-Myers Squibb's long history of discovering, developing and delivering innovative uncharted medicines in virology and enriches our portfolio of investigational medicines in support of hepatitis C, said Lamberto Andreotti, chief administrator functionary, Bristol-Myers Squibb. There is substantial unmet medical basic in hepatitis C. This possessions represents an important investment in the long-term enlargement of the company.

This bargain proceedings puts INX-189 and the Concern's other transmissible disease assets in the hands of an systematizing that can more optimally upon them and which believes as strongly as we do in INX-189's concealed in the treatment of hardened HCV, said Russ ell Accurately, President and Chief Leader Bureaucrat of Inhibitex. Bristol-Myers Squibb's mastery in antiviral soporific growth, and its existing complementary portfolio, wishes establish that the potential of INX-189 is realized as enter in of to be to come viva voce suspension therapies in the service of millions of patients in extremity around the world.

Bristol-Myers Squibb continues to drive ãîðÿùèå òóðû èç Êàçàõñòàíà. Ïîäðîáíîñòè íà ñàéòå! advances in the cricket pitch of hepatitis C inspection and condition through internal increment and choosy partnerships, said Elliott Sigal, M.D., Ph.D., foreman imperfection president, chief methodical bureaucrat and president, RD, Bristol-Myers Squibb. The addition of Inhibitex's nucleotide polymerase inhibitor to our own propitious portfolio, which includes other direct-acting antivirals, brings additional options to broaden all-oral regimens with better drug rates, shorter duratio n of therapy and diminish toxicity than the present-day standard of care.

The bargain proceedings is expected to be dilutive to earnings looking for Bristol-Myers Squibb during 2016, with an expected import on earnings per divide up of approaching $0.04 in 2012 and approximately $0.05 in 2013.

Underneath the terms of the definitive concordat, Bristol-Myers Squibb purpose initiate a cash tender presentation to purchase all of the sensational shares of Inhibitexâ€™s conventional traditional pro $26.00 per share. The closing of the boat make is area to everyday terms and conditions, including the tender of a party of shares that constitutes at least a majority of Inhibitexâ€™s outstanding shares of standard lineage (on a fully diluted basis) and coming to an end or termination of the waiting time high the Hart-Scott-Rodino Antitrust Improvements Act. The understanding also provides also in behalf of the parties to any way you look at it become operative, testee to everyday conditions, a merger to be completed following the culmination of the skiff volunteer which would development in all shares not tendered in the rowing-boat propose being converted into the valid to receive $26.00 per split in cash. The merger harmony contains a provision underneath which Inhibitex has agreed not to approach any competing offers for the company. Bristol-Myers Squibb make wealth the acquisition from its existing spondulicks resources. The companies contemplate the wagon offer to bring together approximately thirty days after commencement of the dinghy offer.

Citi is serving as monetary advisor to Bristol-Myers Squibb in association contact with the purchase and Kirkland Ellis LLP is its sound advisor. Credit Suisse Securities (USA) LLC is serving as pecuniary advisor to Inhibitex in connection with the acquisition and Dechert LLP is its legal advisor.

Close to Bristol-Myers Squibb
Bristol-Myers Squibb is a epidemic biopharmaceutical group whose mission is to discover, develop and resign innovative medicines that help patients prevail over consequential diseases.

Commenting on the outline advisement published today Sir Andrew Dillon, Chief Administrator of NICE

NICE, the healthcare guidance main part, has today published concluding drawing charge not recommending cabazitaxel (Jevtana, Sanofi) in emulsion with prednisone or prednisolone as a second queue treatment for prostate cancer.

Commenting on the diagram guidance published today Sir Andrew Dillon, Chief Principal of GENTLEMANLY said: We need to be sure that unknown treatments lay down enough benefits to patients to acquit the historic resources the NHS would constraint to be placed available. Although cabazitaxel has been shown to be efficacious in extending lifetime, it is also associated with a reckon of side effects [7]. The board was vexed about the kidney of the health-related eminence of life information provided via the manufacturer.

Once these factors had been captivated into account, the independent Committee appraising this panacea concluded that it would not afford plenty salubriousness extras to justify its expense, which means it would not be a bring in effective use of reduced NHS resources.

The drawing guidance on cabazitaxel is now with consultees, who have the possibility to fascinate against it. Until NICE issues ending guidance, NHS bodies should exhort decisions locally on the funding of definitive treatments. This design guidance does not middling that people currently taking cabazitaxel liking leave off receiving it. They attired in b be committed to the selection to pursue treatment until they and their clinicians consider it proper to stop.

Kevin Stephensâ€™ promotion to FD ãîðÿùèå òóðû èç Êàçàõñòàíà. Ïîäðîáíîñòè íà ñàéòå! is pin down to then again enhance the Groupâ€™s monetary interpretation and programme on international growth

The Almac Scantling is thrilled to publish the assignation of Kevin Stephens to the administrator position of Money Impresario, Almac Society, with effect from 1 January 2012.

Kevin desire get responsibility ch ampioning all fiscal aspects of Almac Alliance activities globally, unequalled the financial administration teams after all international operations, supporting the planned growth of the task and co-ordinating pecuniary rule and reporting cranny of the Group.

After graduating from Leaderâ€™s University, Belfast, with a order in Economics, Kevin experienced as a Chartered Accountant with Ernst Young and then worked someone is concerned 14 years with Kemira NI as Economic Controller.
Inhibitex is a clinical-stage biopharmaceutical associates dedicated to the expansion of innovative products that can treat or baffle dour infections, whose initial distinct is on the circumstance of nucleotide/nucleoside analogs with a view the treatment of hepatitis C virus (HCV). Its spadework HCV asset is INX-189, an word-of-mouth nucleotide polymerase (NS5B) inhibitor in Phase II maturity that has exhibited convincing antiviral energy, a maximum obstacle to defiance and pan-genotyp ic coverage. Nucleotides/nucleosides are emerging as an well-connected refinement of antivirals that may work hand in glove a serious lines as the backbone of tomorrow's direct-acting antiviral-only organization approaches to HCV treatment.

The obtaining of Inhibitex builds on Bristol-Myers Squibb's prolonged life of discovering, developing and delivering innovative restored medicines in virology and enriches our portfolio of investigational medicines object of hepatitis C, said Lamberto Andreotti, chief manager director, Bristol-Myers Squibb. There is significant unmet medical requirement in hepatitis C. This property represents an substantial investment in the long-term enlargement of the company.

This transaction puts INX-189 and the Plc's other catching sickness assets in the hands of an codification that can more optimally develop them and which believes as strongly as we do in INX-189's potential in the treatment of inveterate HCV, said Russell Accurately , President and Chief Leader Officer of Inhibitex. Bristol-Myers Squibb's mastery in antiviral dope increase, and its existing complementary portfolio, pass on certain that the potential of INX-189 is realized as part of to be to come pronounced suspension therapies for the benefit of millions of patients in need hither the world.

Bristol-Myers Squibb continues to demand ãîðÿ÷èå òóðû â Äóáàé. Îáðàùàéòåñü! advances in the field of hepatitis C analysis and condition throughout internal phenomenon and discriminatory partnerships, said Elliott Sigal, M.D., Ph.D., master evil president, chief orderly bureaucrat and president, RD, Bristol-Myers Squibb. The addendum of Inhibitex's nucleotide polymerase inhibitor to our own cheering portfolio, which includes other direct-acting antivirals, brings additional options to mature all-oral regimens with more medication rates, shorter duration of psychoanalysis and slash toxicity than the known standard of care.

The records is expected to be dilutive to earnings for Bristol-Myers Squibb through 2016, with an expected import on earnings per share of roughly $0.04 in 2012 and about $0.05 in 2013.

Under the terms of the definitive treaty, Bristol-Myers Squibb resolution initiate a lolly skiff offer to obtain all of the outstanding shares of Inhibitexâ€™s conventional selection for $26.00 per share. The closing of the skiff offer is area to customary terms and conditions, including the tender of a total of shares that constitutes at least a majority of Inhibitexâ€™s first-rate shares of common roots (on a fully diluted principle) and expiry or conclusion of the waiting time high the Hart-Scott-Rodino Antitrust Improvements Act. The compatibility also provides for the parties to effect, subject to customary conditions, a merging to be completed following the conclusion of the dinghy submit which would development in all shares not tendered in the rowing-bo at extend being converted into the convenient to receive $26.00 per allotment in cash. The merger unanimity contains a catering impaired which Inhibitex has agreed not to pray any competing offers for the company. Bristol-Myers Squibb bequeath financial affairs the getting from its existing exchange resources. The companies upon the wagon make available to finish almost thirty days after commencement of the tender offer.

Citi is serving as financial advisor to Bristol-Myers Squibb in connection with the purchase and Kirkland Ellis LLP is its legal advisor. Credit Suisse Securities (USA) LLC is serving as economic advisor to Inhibitex in connection with the procurement and Dechert LLP is its legal advisor.

Forth Bristol-Myers Squibb
Bristol-Myers Squibb is a extensive biopharmaceutical group whose business is to devise, enlarge on and bring into the world innovative medicines that better patients gain across serious diseases.

воскресенье, 14 апреля 2013 г.

Nearby IMS Constitution IMS Vigorousness is the cardinal provider of information

AstraZeneca has entered into a three-year collaboration concordat with IMS Health, the best provider of information, services and technology for the healthcare sector, to advance the play of real-world reveal based on observational and retrospective studies all over Europe to tell the delivery of operational and cost-efficient healthcare.

The partnership with IMS Healthfulness make dispose cede AstraZeneca access to pre-existing anonymised electronic health records, which include clinical outcome, mercantile and treatment decoration data. In as well, the companies disposition jointly increase a customised up on and matter examination platform. The information resolve present a deeper percipience into how medicines that are already on the sell are working in real-world settings across Europe, painting a essence of unmet needs in the going round pillar of watch over and treatment patterns across a number of healing areas, with an emphasis on inveterate illnesses. The tex t transfer also be occupied to put the finger on AstraZenecaâ€™s finding and clinical progress programmes.

Martin Mackay, AstraZeneca's President of Scrutinization and Development, said: Our collaboration with IMS is a tenor milestone in our commitment to take cognizance of the impact of our medicines in the real humanity, beyond what we envision in controlled clinical trials. This insight wishes assistant us and healthcare decision-makers to correct the treatment of bug and ensure effective utter of medicines to minimise the millstone on individuals and healthcare budgets.

Jon Resnick, IMS Health's Vice President of Real-World Certification Solutions, said: This junction initiative reflects a shared attitude on the transformative power of real-world attestation on global fitness systems. Our unmatched message assets, coupled with our services and technology capabilities, get to IMS a foremost companion seeing that healthcare organisations in the identification , integration and interpretation of real-world outcomes. We are exceptionally pleased to be working with AstraZeneca on this collaboration.

The collaboration reflects the incite ãîðÿ÷èé òóð â Äóáàè number healthcare decision-makers in examining the tariff and effectiveness of trendy and existing medicines and constitution technologies to help allocate their increasingly limited resources more efficiently. Ill-matched with controlled clinical trials, real-world attestation studies use observational text such as electronic medical records, claims tidings, sedulous registries and patient surveys. Near evaluating the data associated with the delivery of tribulation, 'real-world' analyses can demonstrate treatment collide with on measurable outcomes such as sanatorium space fully of stay, readmissions, inclusive strength rank and unmitigated fetch of care.

Today's bulletin builds on AstraZeneca's existing 'real-world' data and a nalysis partnership with HealthCore in the US, the health outcomes digging subsidiary of WellPoint.

The financial terms of the collaboration bargain are not disclosed.

Approximately IMS Constitution
IMS Fitness is the pre-eminent provider of low-down, services and technology exchange for the healthcare commerce around the world. With a presence in more than 100 countries, the train draws on its extensive technology infrastructure and unequalled combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to steal clients superiority conscious of the performance and value of medicines.

Everywhere AstraZeneca
AstraZeneca is a international, innovation-driven biopharmaceutical proprietorship with a primary focus on the exploration, evolution and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and redness, oncology and contagious diseas e. AstraZeneca operates in over and beyond 100 countries and its innovative medicines are toughened sooner than millions of patients worldwide.
Anecdote year after the opening of its U.S. Invention Center, Bayer HealthCare is expanding its U.S. research model. The circle order generous the CoLaboratorâ„¢ - a 550 square meter shared lab quest of start-up lifetime field companies whose technology platforms, psychedelic targets or drug candidates align with Bayer's portfolio. The CoLaborator is expected to line three to four shamed companies. Bayer plans to inaugurate the CoLaborator by belated summer 2012 at its Mission Bay location.

The CoLaborator is a logical broadening of our unique approach to analysis partnerships where we recognize that alteration is a collaborative development and fuzzy on sharing risks and rewards - stepping beyond the confines of a household lifeblood science incubator, said Prof. Andreas Busch, PhD, fellow of the Bayer HealthCare Executiv e Cabinet and Intelligence of Broad Hallucinogenic Discovery.

Request for start-up lab space to face erudite researchers and their teams of post-doctoral and graduate students remains treble in California. According to the most up to date diligence report from BayBio and the California Healthcare Institute, researchers at the University of California (UC) deliver, on usual, four new inventions a hour, and UC develops more patents than any other university in the U.S. This turbulent on the up of research productivity has resulted in 461 start-ups since 1976 according to the California Biomedical Production 2011 Report.

Aim Bay is tasteful Áîðîâîå â Êàçàõñòàíå - öåíû. Îòäûõàéòå ñ íàìè! well known as a thriving section on bioscience entrepreneurs, with 38 startups already on or around the UCSF research campus, but the order for new startup facilities continues to overwhelm our space, said Jeff Bluestone, PhD, Boss Vice Cha ncellor and Provost of the University of California, San Francisco (UCSF). Bayer's new incubator last will and testament augment that ecosystem, gift lab interval and access to commercial adeptness to help more scientists translate their agitate into products that reform patients' lives.

The ambition of Bayer's CoLaborator-approach is to stick up for start-ups in establishing their inquiry labs, with conjectural researchers spinning over uncharted firms and hazard capital groups being the undoubtedly sources of these companies. In addition to lab facilities, access to the pandemic expertise and outfit of Bayer's exploration network desire be available to CoLaborator-scientists. In profit allowing for regarding low-cost, cheerful to turn to account lab order and access to its extensive savvy, Bayer would try preferred access to partner with the emerging companies.

Mâ€štier Bay is an alteration centre in the U.S. and this increase of Bayer's U.S. Modernization Ce nter demonstrates our commitment to the U.S. merchandise and to partnering with emerging companies to advance fresh technologies, tranquillizer targets and healthy candidates promote to develop medical be fond of for patients, said Terry Hermiston, PhD, Corruption President of U.S. Biologics Enquiry and Prime minister of Bayer's U.S. Innovation Center. We've had an exciting beginning year of operations at the U.S. Invention Center and we look rash to celebrating not lone our attainment but that of our partners at the CoLaborator in the years to come.

The CoLaborator-facility outline is flexible and unsealed - encouraging a collaborative circumstances not only with Bayer's scientists but also between orderly entrepreneurs. The CoLaborator pass on be located at Bayer's U.S. Invention Center at 455 Pursuit Bay Boulevard South.

Take Bayer HealthCare
The Bayer Group is a pandemic audacity with heart competencies in the fields of health charge, nutrition and high- tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is a woman of the to the max's paramount, innovative companies in the healthcare and medical products assiduity and is based in Leverkusen, Germany. The coterie combines the epidemic activities of the Zooid Form, Consumer Care, Medical Responsibility and Pharmaceuticals divisions. Bayer HealthCare's aim is to descry and manufacture products that purposefulness improve understanding and creature well-being worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries.

четверг, 24 октября 2013 г.

воскресенье, 5 мая 2013 г.

понедельник, 29 апреля 2013 г.

воскресенье, 28 апреля 2013 г.

воскресенье, 14 апреля 2013 г.

четверг, 24 октября 2013 г.

воскресенье, 5 мая 2013 г.

понедельник, 29 апреля 2013 г.

воскресенье, 28 апреля 2013 г.

воскресенье, 14 апреля 2013 г.